Jasmine H Francis1, David H Abramson2, Y Pierre Gobin3, Brian P Marr2, Irwin Tendler4, Scott E Brodie5, Ira J Dunkel4. 1. Ophthalmic Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Ophthalmology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York. Electronic address: francij1@mskcc.org. 2. Ophthalmic Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Ophthalmology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York. 3. Ophthalmic Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; Interventional Neuroradiology, Departments of Radiology, Neurosurgery, and Neurology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York. 4. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York.
Abstract
OBJECTIVE: Assess the usefulness of second-course ophthalmic artery chemosurgery (OAC) for patients with intraocular retinoblastoma that recurred after prior OAC. This study evaluated the efficacy and toxicity of second-course OAC. DESIGN: Single-arm retrospective study of 29 eyes of 30 patients treated with second-course OAC at Memorial Sloan Kettering Cancer Center between May 2006 and July 2013, with a median follow-up of 25.9 months. PARTICIPANTS: Retinoblastoma patients who underwent a course of OAC, with a minimum of 2 months of progression-free follow-up at monthly examinations, but who subsequently received additional OAC for recurrent tumor. METHODS: To determine efficacy, Kaplan-Meier survival estimates were generated and the Mantel-Cox test was used to compare curves. To determine toxicity, electroretinography (ERG) amplitudes were measured in response to 30-Hz photopic flicker stimulation before and after OAC treatment; systemic adverse events were graded according to the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE 4.0). MAIN OUTCOME MEASURES: For efficacy, ocular progression-free survival, ocular event-free survival (e.g., enucleation, external-beam radiation, or intravitreal melphalan), and ocular survival. For toxicity, peak-to-peak comparisons between ERG studies before and after OAC treatment and CTCAE 4.0-graded systemic adverse events. RESULTS: Fifty percent of all recurrences were within 4.4 months and 90% were within 16 months of completion of the first course of OAC. The 2-year Kaplan-Meier ocular survival, event-free survival, and progression-free survival estimates after second-course OAC were 82.8% (95% confidence interval [CI], 60.1%-93.2%), 57.3% (95% CI, 36.1%-73.7%), and 26.5% (95% CI, 11.0%-45.0%), respectively. All eyes without vitreous seeding were progression free, whereas eyes with vitreous seeding were associated significantly with worse ocular survival after second-course OAC (P = 0.03). After second-course OAC, 90% of eyes had stable or improved ERG responses. Of all evaluable cases, there was no increased risk of systemic toxicity during the second course compared with the initial course of OAC. CONCLUSIONS: Retinoblastoma eyes requiring second-course OAC after initial OAC treatment have good salvage rates, and the treatment has an acceptable ocular and systemic toxicity profile. However, these eyes often require additional (third- or fourth-course) OAC or other treatment methods because of progression of disease after second-line OAC, particularly if vitreous seeds are present at the time of initial OAC failure.
OBJECTIVE: Assess the usefulness of second-course ophthalmic artery chemosurgery (OAC) for patients with intraocular retinoblastoma that recurred after prior OAC. This study evaluated the efficacy and toxicity of second-course OAC. DESIGN: Single-arm retrospective study of 29 eyes of 30 patients treated with second-course OAC at Memorial Sloan Kettering Cancer Center between May 2006 and July 2013, with a median follow-up of 25.9 months. PARTICIPANTS: Retinoblastomapatients who underwent a course of OAC, with a minimum of 2 months of progression-free follow-up at monthly examinations, but who subsequently received additional OAC for recurrent tumor. METHODS: To determine efficacy, Kaplan-Meier survival estimates were generated and the Mantel-Cox test was used to compare curves. To determine toxicity, electroretinography (ERG) amplitudes were measured in response to 30-Hz photopic flicker stimulation before and after OAC treatment; systemic adverse events were graded according to the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE 4.0). MAIN OUTCOME MEASURES: For efficacy, ocular progression-free survival, ocular event-free survival (e.g., enucleation, external-beam radiation, or intravitreal melphalan), and ocular survival. For toxicity, peak-to-peak comparisons between ERG studies before and after OAC treatment and CTCAE 4.0-graded systemic adverse events. RESULTS: Fifty percent of all recurrences were within 4.4 months and 90% were within 16 months of completion of the first course of OAC. The 2-year Kaplan-Meier ocular survival, event-free survival, and progression-free survival estimates after second-course OAC were 82.8% (95% confidence interval [CI], 60.1%-93.2%), 57.3% (95% CI, 36.1%-73.7%), and 26.5% (95% CI, 11.0%-45.0%), respectively. All eyes without vitreous seeding were progression free, whereas eyes with vitreous seeding were associated significantly with worse ocular survival after second-course OAC (P = 0.03). After second-course OAC, 90% of eyes had stable or improved ERG responses. Of all evaluable cases, there was no increased risk of systemic toxicity during the second course compared with the initial course of OAC. CONCLUSIONS:Retinoblastoma eyes requiring second-course OAC after initial OAC treatment have good salvage rates, and the treatment has an acceptable ocular and systemic toxicity profile. However, these eyes often require additional (third- or fourth-course) OAC or other treatment methods because of progression of disease after second-line OAC, particularly if vitreous seeds are present at the time of initial OAC failure.
Authors: Sandra Bracco; Sara Leonini; Sonia De Francesco; Samuele Cioni; Paola Gennari; Ignazio Maria Vallone; Pietro Piu; Daniela Galimberti; Daniele Giuseppe Romano; Mauro Caini; Mariacarla De Luca; Paolo Toti; Paolo Galluzzi; Theodora Hadjistilianou; Alfonso Cerase Journal: Br J Ophthalmol Date: 2013-07-12 Impact factor: 4.638
Authors: Carol L Shields; Fairooz P Manjandavida; Sruthi Arepalli; Swathi Kaliki; Sara E Lally; Jerry A Shields Journal: JAMA Ophthalmol Date: 2014-03 Impact factor: 7.389
Authors: Jasmine H Francis; Paula Schaiquevich; Emiliano Buitrago; María José Del Sole; Gustavo Zapata; J Oscar Croxatto; Brian P Marr; Scott E Brodie; Alejandro Berra; Guillermo L Chantada; David H Abramson Journal: Ophthalmology Date: 2014-05-10 Impact factor: 12.079
Authors: Carol L Shields; Fairooz P Manjandavida; Sara E Lally; Giulia Pieretti; Sruthi A Arepalli; Emi H Caywood; Pascal Jabbour; Jerry A Shields Journal: Ophthalmology Date: 2014-03-21 Impact factor: 12.079
Authors: A Donfrancesco; A Jenkner; A Castellano; I Ilari; G M Milano; L De Sio; R Cozza; P Fidani; G Deb; C De Laurentis; A Inserra; C Dominici Journal: Acta Paediatr Suppl Date: 2004-05
Authors: Y Pierre Gobin; Ira J Dunkel; Brian P Marr; Jasmine H Francis; Scott E Brodie; David H Abramson Journal: PLoS One Date: 2012-09-18 Impact factor: 3.240
Authors: Jasmine H Francis; David H Abramson; Y Pierre Gobin; Brian P Marr; Ira J Dunkel; Elyn R Riedel; Scott E Brodie Journal: PLoS One Date: 2014-01-20 Impact factor: 3.240
Authors: David H Abramson; Armida W M Fabius; Jasmine H Francis; Brian P Marr; Ira J Dunkel; Scott E Brodie; Anna Escuder; Y Pierre Gobin Journal: Ophthalmic Genet Date: 2017-01-17 Impact factor: 1.803
Authors: Matthew D Karl; Jasmine H Francis; Saipriya Iyer; Brian Marr; David H Abramson Journal: J Pediatr Ophthalmol Strabismus Date: 2017-01-17 Impact factor: 1.402
Authors: Liya Xu; Ashley Polski; Rishvanth K Prabakar; Mark W Reid; Patricia Chevez-Barrios; Rima Jubran; Jonathan W Kim; Peter Kuhn; David Cobrinik; James Hicks; Jesse L Berry Journal: Mol Cancer Res Date: 2020-05-20 Impact factor: 5.852
Authors: Mary E Kim; Liya Xu; Rishvanth K Prabakar; Lishuang Shen; Chen-Ching Peng; Peter Kuhn; Xiaowu Gai; James Hicks; Jesse L Berry Journal: J Vis Exp Date: 2021-09-07 Impact factor: 1.424
Authors: Helen Dimaras; Timothy W Corson; David Cobrinik; Abby White; Junyang Zhao; Francis L Munier; David H Abramson; Carol L Shields; Guillermo L Chantada; Festus Njuguna; Brenda L Gallie Journal: Nat Rev Dis Primers Date: 2015-08-27 Impact factor: 52.329
Authors: Lucy V Cobbs; Jasmine H Francis; Ira J Dunkel; Y Pierre Gobin; Scott E Brodie; David H Abramson Journal: Pediatr Blood Cancer Date: 2020-12-23 Impact factor: 3.838
Authors: David H Abramson; Armida W M Fabius; Reda Issa; Jasmine H Francis; Brian P Marr; Ira J Dunkel; Y Pierre Gobin Journal: PLoS One Date: 2015-12-28 Impact factor: 3.240